Combining the farnesyltransferase inhibitor lonafarnib with paclitaxel results in enhanced growth inhibitory effects on human ovarian cancer models in vitro and in vivo.

@article{Taylor2008CombiningTF,
  title={Combining the farnesyltransferase inhibitor lonafarnib with paclitaxel results in enhanced growth inhibitory effects on human ovarian cancer models in vitro and in vivo.},
  author={Stacey A Taylor and Cindy H Marrinan and Gongjie Liu and Lissette Nale and W. Robert Bishop and Paul T. Kirschmeier and Ming Liu and Brian J. Long},
  journal={Gynecologic oncology},
  year={2008},
  volume={109 1},
  pages={97-106}
}
OBJECTIVES To determine the effects of combining lonafarnib with paclitaxel on the growth of human ovarian cancer cells and tumor xenografts as well as to monitor a pharmacodynamic marker of farnesyltransferase inhibition (HDJ-2) in peripheral blood mononuclear cells (PBMCs) isolated from tumor-bearing animals after treatment with this combination. METHODS Proliferation of A2780, PA-1, IGROV-1, and TOV-112D cells was assessed after treatment with lonafarnib and paclitaxel. Cell cycle… CONTINUE READING

Similar Papers

Loading similar papers…